Product
Help
Pricing
About
Jobs
Log in
Get started
Award
Add to collection
ESR-14-10627
Funder:
AstraZeneca
Topic:
Diabetes Treatment and Management
Subfield:
Endocrinology, Diabetes and Metabolism
Field:
Medicine
Domain:
Health Sciences
Funded outputs count:
5
Funder award ID:
ESR-14-10627
OpenAlex ID:
G8050170794
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial
2026
·
Sheila T. Kimura-Medorima
, Daniela C Oliveira
, et al.
·
Cardiovascular Diabetology
·
1
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial
2021
·
Ikaro Breder
, Vaneza Lira W. Wolf
, et al.
·
Diabetes & Metabolism
·
6
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
2021
·
Vaneza Lira W. Wolf
, Ikaro Breder
, et al.
·
Nutrition and Diabetes
·
21
PDF
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
2021
·
ADDENDA-BHS2 trial investigators
, Andrei C. Sposito
, et al.
·
Cardiovascular Diabetology
·
95
PDF
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
2019
·
ADDENDA-BHS2 trial investigators
, Riobaldo M. R. Cintra
, et al.
·
Diabetology & Metabolic Syndrome
·
17
PDF
Show more works
View as search